Neoadjuvant leukocyte interleukin injection immunotherapy improves overall survival in low-risk locally advanced head and neck squamous cell carcinoma -the <i>IT-MATTERS</i> study.

Other efficacy endpoints While there were no significant LI + CIZ + SOC advantages over SOC alone for PFS and LRC in the overall population, a favorable trend was observed for the ITT LR group in the case of the PFS ( Supplementary Figure S6 ), with a hazard ratio of 0.76 (95% CI: 0.55–1.04).

also in 805 other papers